查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1513682

全球寵物過敏治療市場：產業分析、規模、佔有率、成長、趨勢、預測，2024-2031

Pet Allergy Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 156 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

本報告發佈了全球寵物過敏治療市場的綜合報告。詳細分析市場驅動因素、趨勢、機會和課題等關鍵市場動態，以提供對市場前景的深入見解。

關鍵見解

  • 寵物過敏治療市場規模（2024 年）：26.712 億美元
  • 預測市場金額（2031 年）：3,930,760,000 美元
  • 全球市場成長率（2024-2031 年複合年增長率）：5.7%

寵物過敏治療市場 - 研究範圍

寵物過敏是全世界寵物及其主人的主要健康問題。寵物過敏治療市場包括多種治療方案，旨在控制貓和狗等寵物引起的過敏反應。這些治療包括藥物治療、免疫療法、過敏原避免策略和新的生物療法。該市場服務於獸醫診所、醫院、寵物護理中心和家庭護理設施，滿足寵物主人對有效過敏管理解決方案不斷增長的需求。

推動市場成長的因素：

全球寵物過敏治療市場受到多種因素的推動，包括寵物擁有量的增加、對寵物過敏的認識不斷提高以及獸醫學的進步。寵物主人和寵物中過敏性疾病的流行增加了對有效治療方案的需求。診斷工具和治療方法的技術創新提高了診斷準確性和治療效果，進一步推動市場成長。此外，寵物保險覆蓋範圍的擴大和寵物醫療基礎設施的投資也有助於市場擴張。

市場限制因素：

雖然寵物過敏治療市場有望實現成長，但它面臨著監管合規性、治療結果的可變性以及主人對處方治療的依從性等方面的課題。獸藥和生物製品的監管框架給製造商和醫療保健提供者帶來了合規負擔，影響了市場動態和業務策略。此外，一些地區先進治療的高成本和有限的報銷範圍阻礙了市場滲透，特別是在新興市場。

市場機會：

由於人口趨勢、寵物日益人性化以及消費者對寵物保健產品和服務的偏好不斷變化，寵物過敏治療市場呈現出巨大的成長機會。遠距醫療和數位健康解決方案的整合促進了遠端諮詢並改善了業主獲得獸醫護理的機會。此外，獸藥公司、寵物食品製造商和過敏專家之間的合作將促進治療方案和過敏原管理策略的創新。為了利用新的市場機會，對研究和開發的策略性投資以及針對寵物主人和獸醫專業人員的教育舉措至關重要。

本報告涵蓋的主要問題

  • 推動全球寵物過敏治療市場成長的因素有哪些？
  • 哪些治療和診斷工具越來越受到寵物主人和獸醫專業人士的歡迎？
  • 科技進步如何改變寵物過敏治療市場的競爭格局？
  • 誰是寵物過敏治療市場的主要參與者？
  • 全球寵物過敏治療市場的新趨勢和未來前景如何？

目錄

第 1 章執行摘要

第二章市場概述

  • 市場範圍/分類
  • 市場定義/範圍/限制
  • 包含和排除

第三章主要市場趨勢

  • 影響市場的主要趨勢
  • 產品創新/發展趨勢

第 4 章增值見解

  • 產品採用率分析
  • 依品牌劃分的產品 USP/功能分析
  • 各國的監理狀況
  • 近期產品核准/發佈
  • 疾病流行病學
  • 波特的分析
  • 杵分析
  • 價值鏈分析
  • 未滿足的需求

第五章市場背景

  • 宏觀經濟因素
  • 預測因子 - 相關性和影響
  • 市場動態

第六章全球市場需求（金額或規模，百萬美元）分析

  • 2019-2023 年過去的市值（百萬美元）分析
  • 2024-2031 年當前及未來市場規模（百萬美元）預測
    • 年成長趨勢分析
    • 絕對美元機會分析
  • 收入機會情境 - 可能/保守/樂觀

第 7 章全球市場分析：依藥物類別

  • 簡介/主要發現
  • 2019-2023 年歷史市場規模（百萬美元）分析（依藥物類別）
  • 2024-2031 年當前和未來市場規模（百萬美元）分析和預測（依藥物類別）
    • 抗組織胺藥
    • 皮質類固醇
    • 免疫治療
    • 抗生素
  • 市場吸引力分析：依藥物類別

第 8 章全球市場分析：依跡象

  • 簡介/主要發現
  • 2019-2023 年歷史市場規模（百萬美元）分析（依指標）
  • 2024-2031 年當前和未來市場規模（百萬美元）分析和預測（依指標）
    • 過敏性皮膚炎
    • 食物過敏
    • 跳蚤/蟎過敏
    • 接觸過敏
  • 市場吸引力分析：依指標分類

第 9 章全球市場分析：依寵物類型

  • 簡介/主要發現
  • 2019-2023 年過去的市場規模（百萬美元）分析（依寵物類型）
  • 2024-2031 年當前和未來市場規模（百萬美元）分析和預測（依寵物類型）
    • 狗
    • 貓
    • 囓齒動物/兔子
  • 市場吸引力分析：依寵物類型

第 10 章全球市場分析：依管理途徑

  • 簡介/主要發現
  • 2019-2023 年依管理途徑劃分的歷史市場規模（百萬美元）分析
  • 2024-2031 年當前和未來市場規模（百萬美元）分析和預測（依管理方式）
    • 口服製劑
    • 注射
    • 本地
  • 市場吸引力分析：依給藥途徑

第 11 章世界市場分析：依通路

  • 簡介/主要發現
  • 2019-2023 年過去的市場規模（百萬美元）分析（依分銷管道）
  • 2024-2031 年當前和未來市場規模（百萬美元）分析和預測（依分銷管道）
    • 動物醫院
    • 零售藥局
    • 網路藥局
    • 其他
  • 市場吸引力分析：依分銷管道

第 12 章世界市場分析：依地區

  • 簡介/主要發現
  • 2019-2023 年依地區劃分的過往市場規模（百萬美元）分析
  • 2024-2031 年當前和未來市場規模（百萬美元）分析和預測（依地區）
    • 北美
    • 拉丁美洲
    • 歐洲
    • 南亞
    • 東亞
    • 大洋洲
    • 中東/非洲
  • 市場吸引力分析：依地區劃分

第十三章北美市場分析

第 14 章拉丁美洲市場分析

第 15 章歐洲市場分析

第16章東亞市場分析

第十七章南亞市場分析

第18章大洋洲市場分析

第十九章中東/非洲市場分析

第20章市場結構分析

  • 市場分析：依公司層級
  • 主要企業市佔率分析（%）
  • 市場現況分析

第21章競爭分析

  • 競爭對手儀表板
  • 主要發展分析
  • 主要參與者的品牌和推廣策略
  • 衝突詳情
    • Zoetis Animal Healthcare
    • Merck and Co.Inc.（US）
    • Boehringer Ingelheim GmbH
    • Elanco Animal Health Incorporated
    • Bayer AG
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Virbac SA
    • IDEXX Laboratories, Inc.
    • Ceva Sante Animale
    • Kindred Biosciences, Inc.
    • Phirbo Animal Health
    • Norbrook Laboratories Limited
    • Vetiquinol SA
    • Neogen Corporation
    • PetIQ, Inc.
    • Huvepharma AD
    • Chanelle Pharma Group Limited
    • Kepro
    • Biogenesis Bago

第 22 章使用的假設與縮寫

第23章研究方法

簡介目錄
Product Code: PMRREP28603

Persistence Market Research has recently released a comprehensive report on the global Pet Allergy Treatment Market. The report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market landscape.

Key Insights:

  • Pet Allergy Treatment Market Size (2024E): USD 2,671.20 million
  • Projected Market Value (2031F): USD 3,930.76 million
  • Global Market Growth Rate (CAGR 2024 to 2031):5.7%

Pet Allergy Treatment Market - Report Scope:

Pet allergies represent a significant health concern for both pets and their owners globally. The market for pet allergy treatment encompasses a range of therapeutic options aimed at managing allergic reactions caused by pets, such as cats and dogs. These treatments include medications, immunotherapy, allergen avoidance strategies, and emerging biologic therapies. The market caters to veterinary clinics, hospitals, pet care centers, and homecare settings, addressing a growing demand from pet owners seeking effective allergy management solutions.

Market Growth Drivers:

The global pet allergy treatment market is driven by several factors, including increasing pet ownership, rising awareness about pet allergies, and advancements in veterinary medicine. The growing prevalence of allergic conditions among pet owners and pets alike underscores the need for effective treatment options. Technological innovations in diagnostic tools and treatment modalities further enhance market growth, improving diagnostic accuracy and treatment efficacy. Moreover, the expanding pet insurance coverage and investments in pet healthcare infrastructure contribute to market expansion.

Market Restraints:

Despite promising growth prospects, the pet allergy treatment market faces challenges related to regulatory compliance, variability in treatment outcomes, and pet owner adherence to prescribed therapies. Regulatory frameworks governing veterinary pharmaceuticals and biologics impose compliance burdens on manufacturers and healthcare providers, influencing market dynamics and operational strategies. Additionally, the high cost of advanced treatments and limited reimbursement coverage in some regions hinder market penetration, particularly in emerging economies.

Market Opportunities:

The pet allergy treatment market presents significant growth opportunities driven by demographic trends, increasing pet humanization, and evolving consumer preferences for pet healthcare products and services. The integration of telemedicine and digital health solutions facilitates remote consultations and enhances pet owner access to veterinary care. Furthermore, collaborations between veterinary pharmaceutical companies, pet food manufacturers, and allergy specialists foster innovation in treatment protocols and allergen management strategies. Strategic investments in research and development, along with educational initiatives targeting pet owners and veterinary professionals, are essential to capitalize on emerging market opportunities.

Key Questions Answered in the Report:

  • What factors are driving the growth of the pet allergy treatment market globally?
  • Which treatment modalities and diagnostic tools are gaining traction among pet owners and veterinary professionals?
  • How are technological advancements reshaping the competitive landscape of the pet allergy treatment market?
  • Who are the key players contributing to the pet allergy treatment market, and what strategies are they employing to maintain market leadership?
  • What are the emerging trends and future prospects in the global pet allergy treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global pet allergy treatment market, including pharmaceutical companies, veterinary clinics, and biotechnology firms, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop novel therapies, diagnostic tests, and allergen management solutions, catering to diverse pet owner preferences and clinical needs. Collaborations with pet healthcare providers, regulatory agencies, and pet insurance companies facilitate market access and promote technology adoption. Moreover, emphasis on evidence-based practice, veterinary education, and pet owner engagement enhances treatment outcomes and supports sustainable market growth in the evolving landscape of pet allergy management.

Key Companies Profiled:

  • Zoetis Animal Healthcare
  • Merck and Co Inc.
  • Boehringer Ingelheim GmbH
  • Elanco Animal Health Incorporated
  • Bayer AG
  • Vetoquinol S.A.
  • Dechra Pharmaceuticals PLC
  • Virbac SA
  • IDEXX Laboratories, Inc.
  • Ceva Sante Animale
  • Kindred Biosciences, Inc.
  • Phirbo Animal Health
  • Norbrook Laboratories Limited
  • Vetiquinol SA
  • Neogen Corporation
  • PetIQ, Inc.
  • Huvepharma AD

Key Segments of Pet Allergy Treatment Industry Research

By Drug Class:

  • Antihistamines
  • Corticosteroids
  • Immunotherapy
  • Antibiotics

By Indication:

  • Allergic Dermatitis
  • Food Allergy
  • Fleabite Allergy
  • Contact Allergy

By Pet Type:

  • Dogs
  • Cats
  • Rodents & Rabbits

By Route of Administration:

  • Oral
  • Injectable
  • Topical

By Distribution Channel:

  • Veterinary Hospitals
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand-side Trends
  • 1.3. Supply-side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Value Added Insights

  • 4.1. Product Adoption Analysis
  • 4.2. Product USPs/Features Analysis, By Brands
  • 4.3. Regulatory Landscape, By Country
  • 4.4. Recent Product Approval/Launches
  • 4.5. Disease Epidemiology
  • 4.6. Porter's Analysis
  • 4.7. PESTLE Analysis
  • 4.8. Value Chain Analysis
  • 4.9. Unmet Needs

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global Healthcare Expenditure Outlook
    • 5.1.2. Global Pharmaceutical Market Outlook
    • 5.1.3. Global Animal Healthcare Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Rate of Pet Adoption
    • 5.2.2. Increase in Research and Development
    • 5.2.3. Strategic Collaborations among players
    • 5.2.4. Cost of Product
    • 5.2.5. Business Expansions
    • 5.2.6. Frequency of Product Approval
    • 5.2.7. Pet Care Insurance
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2019-2023 and Forecast, 2024-2031

  • 6.1. Historical Market Value (US$ Million) Analysis, 2019-2023
  • 6.2. Current and Future Market Size (US$ Million) Projections, 2024-2031
    • 6.2.1. Y-o-Y Growth Trend Analysis
    • 6.2.2. Absolute $ Opportunity Analysis
  • 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic

7. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Drug Class

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2019-2023
  • 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2024-2031
    • 7.3.1. Antihistamines
    • 7.3.2. Corticosteroids
    • 7.3.3. Immunotherapy
    • 7.3.4. Antibiotics
  • 7.4. Market Attractiveness Analysis By Drug Class

8. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Indication

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Million) Analysis By Indication, 2019-2023
  • 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2024-2031
    • 8.3.1. Allergic Dermatitis
    • 8.3.2. Food Allergy
    • 8.3.3. Fleabite Allergy
    • 8.3.4. Contact Allergy
  • 8.4. Market Attractiveness Analysis By Indication

9. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Pet Type

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Million) Analysis By Pet Type, 2019-2023
  • 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Pet Type, 2024-2031
    • 9.3.1. Dogs
    • 9.3.2. Cats
    • 9.3.3. Rodents and rabbits
  • 9.4. Market Attractiveness Analysis By Pet Type

10. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Route of Administration

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2019-2023
  • 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2024-2031
    • 10.3.1. Oral
    • 10.3.2. Injectable
    • 10.3.3. Topical
  • 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Market Analysis 2019-2023 and Forecast 2024-2031, By Distribution Channel

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2019-2023
  • 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2024-2031
    • 11.3.1. Veterinary Hospitals
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
    • 11.3.4. Others
  • 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2019-2023 and Forecast 2024-2031, by Region

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Million) Analysis By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2024-2031
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East and Africa
  • 12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2031

  • 13.1. Introduction / Key Findings
  • 13.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 13.3.1. By Country
      • 13.3.1.1. United States
      • 13.3.1.2. Canada
    • 13.3.2. By Drug Class
    • 13.3.3. By Indication
    • 13.3.4. By Pet Type
    • 13.3.5. By Route of Administration
    • 13.3.6. By Distribution Channel
  • 13.4. Market Attractiveness Analysis By Region
    • 13.4.1. By Country
    • 13.4.2. By Drug Class
    • 13.4.3. By Indication
    • 13.4.4. By Pet Type
    • 13.4.5. By Route of Administration
    • 13.4.6. By Distribution Channel
  • 13.5. Market trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. United States Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug Class
        • 13.8.1.2.2. By Indication
        • 13.8.1.2.3. By Pet Type
        • 13.8.1.2.4. By Route of Administration
        • 13.8.1.2.5. By Distribution Channel
    • 13.8.2. Canada Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug Class
        • 13.8.2.2.2. By Indication
        • 13.8.2.2.3. By Pet Type
        • 13.8.2.2.4. By Route of Administration
        • 13.8.2.2.5. By Distribution Channel

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2031

  • 14.1. Introduction / Key Findings
  • 14.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Drug Class
    • 14.3.3. By Indication
    • 14.3.4. By Pet Type
    • 14.3.5. By Route of Administration
    • 14.3.6. By Distribution Channel
  • 14.4. Market Attractiveness Analysis By Region
    • 14.4.1. By Country
    • 14.4.2. By Drug Class
    • 14.4.3. By Indication
    • 14.4.4. By Pet Type
    • 14.4.5. By Route of Administration
    • 14.4.6. By Distribution Channel
  • 14.5. Market trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug Class
        • 14.8.1.2.2. By Indication
        • 14.8.1.2.3. By Pet Type
        • 14.8.1.2.4. By Route of Administration
        • 14.8.1.2.5. By Distribution Channel
    • 14.8.2. Mexico Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug Class
        • 14.8.2.2.2. By Indication
        • 14.8.2.2.3. By Pet Type
        • 14.8.2.2.4. By Route of Administration
        • 14.8.2.2.5. By Distribution Channel
    • 14.8.3. Argentina Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug Class
        • 14.8.3.2.2. By Indication
        • 14.8.3.2.3. By Pet Type
        • 14.8.3.2.4. By Route of Administration
        • 14.8.3.2.5. By Distribution Channel

15. Europe Market Analysis 2019-2023 and Forecast 2024-2031

  • 15.1. Introduction / Key Findings
  • 15.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 15.3.1. By Country
      • 15.3.1.1. Germany
      • 15.3.1.2. France
      • 15.3.1.3. Spain
      • 15.3.1.4. Russia
      • 15.3.1.5. Italy
      • 15.3.1.6. BENELUX
      • 15.3.1.7. United Kingdom
      • 15.3.1.8. Rest of Europe
    • 15.3.2. By Drug Class
    • 15.3.3. By Indication
    • 15.3.4. By Pet Type
    • 15.3.5. By Route of Administration
    • 15.3.6. By Distribution Channel
  • 15.4. Market Attractiveness Analysis By Region
    • 15.4.1. By Country
    • 15.4.2. By Drug Class
    • 15.4.3. By Indication
    • 15.4.4. By Pet Type
    • 15.4.5. By Route of Administration
    • 15.4.6. By Distribution Channel
  • 15.5. Market trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. Germany Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug Class
        • 15.8.1.2.2. By Indication
        • 15.8.1.2.3. By Pet Type
        • 15.8.1.2.4. By Route of Administration
        • 15.8.1.2.5. By Distribution Channel
    • 15.8.2. France Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug Class
        • 15.8.2.2.2. By Indication
        • 15.8.2.2.3. By Pet Type
        • 15.8.2.2.4. By Route of Administration
        • 15.8.2.2.5. By Distribution Channel
    • 15.8.3. Spain Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug Class
        • 15.8.3.2.2. By Indication
        • 15.8.3.2.3. By Pet Type
        • 15.8.3.2.4. By Route of Administration
        • 15.8.3.2.5. By Distribution Channel
    • 15.8.4. Russia Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug Class
        • 15.8.4.2.2. By Indication
        • 15.8.4.2.3. By Pet Type
        • 15.8.4.2.4. By Route of Administration
        • 15.8.4.2.5. By Distribution Channel
    • 15.8.5. Italy Market Analysis
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Drug Class
        • 15.8.5.2.2. By Indication
        • 15.8.5.2.3. By Pet Type
        • 15.8.5.2.4. By Route of Administration
        • 15.8.5.2.5. By Distribution Channel
    • 15.8.6. BENELUX Market Analysis
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Drug Class
        • 15.8.6.2.2. By Indication
        • 15.8.6.2.3. By Pet Type
        • 15.8.6.2.4. By Route of Administration
        • 15.8.6.2.5. By Distribution Channel
    • 15.8.7. United Kingdom Market Analysis
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Drug Class
        • 15.8.7.2.2. By Indication
        • 15.8.7.2.3. By Pet Type
        • 15.8.7.2.4. By Route of Administration
        • 15.8.7.2.5. By Distribution Channel

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2031

  • 16.1. Introduction / Key Findings
  • 16.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Drug Class
    • 16.3.3. By Indication
    • 16.3.4. By Pet Type
    • 16.3.5. By Route of Administration
    • 16.3.6. By Distribution Channel
  • 16.4. Market Attractiveness Analysis By Region
    • 16.4.1. By Country
    • 16.4.2. By Drug Class
    • 16.4.3. By Indication
    • 16.4.4. By Pet Type
    • 16.4.5. By Route of Administration
    • 16.4.6. By Distribution Channel
  • 16.5. Market trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug Class
        • 16.8.1.2.2. By Indication
        • 16.8.1.2.3. By Pet Type
        • 16.8.1.2.4. By Route of Administration
        • 16.8.1.2.5. By Distribution Channel
    • 16.8.2. Japan Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug Class
        • 16.8.2.2.2. By Indication
        • 16.8.2.2.3. By Pet Type
        • 16.8.2.2.4. By Route of Administration
        • 16.8.2.2.5. By Distribution Channel
    • 16.8.3. South Korea Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Drug Class
        • 16.8.3.2.2. By Indication
        • 16.8.3.2.3. By Pet Type
        • 16.8.3.2.4. By Route of Administration
        • 16.8.3.2.5. By Distribution Channel

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2031

  • 17.1. Introduction / Key Findings
  • 17.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Indonesia
      • 17.3.1.3. Thailand
      • 17.3.1.4. Philippines
      • 17.3.1.5. Malaysia
      • 17.3.1.6. Vietnam
      • 17.3.1.7. Rest of South Asia
    • 17.3.2. By Drug Class
    • 17.3.3. By Indication
    • 17.3.4. By Pet Type
    • 17.3.5. By Route of Administration
    • 17.3.6. By Distribution Channel
  • 17.4. Market Attractiveness Analysis By Region
    • 17.4.1. By Country
    • 17.4.2. By Drug Class
    • 17.4.3. By Indication
    • 17.4.4. By Pet Type
    • 17.4.5. By Route of Administration
    • 17.4.6. By Distribution Channel
  • 17.5. Market trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. India Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug Class
        • 17.8.1.2.2. By Indication
        • 17.8.1.2.3. By Pet Type
        • 17.8.1.2.4. By Route of Administration
        • 17.8.1.2.5. By Distribution Channel
    • 17.8.2. Indonesia Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug Class
        • 17.8.2.2.2. By Indication
        • 17.8.2.2.3. By Pet Type
        • 17.8.2.2.4. By Route of Administration
        • 17.8.2.2.5. By Distribution Channel
    • 17.8.3. Thailand Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug Class
        • 17.8.3.2.2. By Indication
        • 17.8.3.2.3. By Pet Type
        • 17.8.3.2.4. By Route of Administration
        • 17.8.3.2.5. By Distribution Channel
    • 17.8.4. Philippines Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug Class
        • 17.8.4.2.2. By Indication
        • 17.8.4.2.3. By Pet Type
        • 17.8.4.2.4. By Route of Administration
        • 17.8.4.2.5. By Distribution Channel
    • 17.8.5. Malaysia Market Analysis
      • 17.8.5.1. Introduction
      • 17.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.5.2.1. By Drug Class
        • 17.8.5.2.2. By Indication
        • 17.8.5.2.3. By Pet Type
        • 17.8.5.2.4. By Route of Administration
        • 17.8.5.2.5. By Distribution Channel
    • 17.8.6. Vietnam Market Analysis
      • 17.8.6.1. Introduction
      • 17.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.6.2.1. By Drug Class
        • 17.8.6.2.2. By Indication
        • 17.8.6.2.3. By Pet Type
        • 17.8.6.2.4. By Route of Administration
        • 17.8.6.2.5. By Distribution Channel

18. Oceania Market Analysis 2019-2023 and Forecast 2024-2031

  • 18.1. Introduction / Key Findings
  • 18.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Drug Class
    • 18.3.3. By Indication
    • 18.3.4. By Pet Type
    • 18.3.5. By Route of Administration
    • 18.3.6. By Distribution Channel
  • 18.4. Market Attractiveness Analysis By Region
    • 18.4.1. By Country
    • 18.4.2. By Drug Class
    • 18.4.3. By Indication
    • 18.4.4. By Pet Type
    • 18.4.5. By Route of Administration
    • 18.4.6. By Distribution Channel
  • 18.5. Market trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Drug Class
        • 18.8.1.2.2. By Indication
        • 18.8.1.2.3. By Pet Type
        • 18.8.1.2.4. By Route of Administration
        • 18.8.1.2.5. By Distribution Channel
    • 18.8.2. New Zealand Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Drug Class
        • 18.8.2.2.2. By Indication
        • 18.8.2.2.3. By Pet Type
        • 18.8.2.2.4. By Route of Administration
        • 18.8.2.2.5. By Distribution Channel

19. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2031

  • 19.1. Introduction / Key Findings
  • 19.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2024-2031
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. Egypt
      • 19.3.1.4. Israel
      • 19.3.1.5. South Africa
      • 19.3.1.6. Northern Africa
      • 19.3.1.7. Rest of Middle East and Africa
    • 19.3.2. By Drug Class
    • 19.3.3. By Indication
    • 19.3.4. By Pet Type
    • 19.3.5. By Route of Administration
    • 19.3.6. By Distribution Channel
  • 19.4. Market Attractiveness Analysis By Region
    • 19.4.1. By Country
    • 19.4.2. By Drug Class
    • 19.4.3. By Indication
    • 19.4.4. By Pet Type
    • 19.4.5. By Route of Administration
    • 19.4.6. By Distribution Channel
  • 19.5. Market trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Market Analysis
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Drug Class
        • 19.8.1.2.2. By Indication
        • 19.8.1.2.3. By Pet Type
        • 19.8.1.2.4. By Route of Administration
        • 19.8.1.2.5. By Distribution Channel
    • 19.8.2. Turkey Market Analysis
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Drug Class
        • 19.8.2.2.2. By Indication
        • 19.8.2.2.3. By Pet Type
        • 19.8.2.2.4. By Route of Administration
        • 19.8.2.2.5. By Distribution Channel
    • 19.8.3. Egypt Market Analysis
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Drug Class
        • 19.8.3.2.2. By Indication
        • 19.8.3.2.3. By Pet Type
        • 19.8.3.2.4. By Route of Administration
        • 19.8.3.2.5. By Distribution Channel
    • 19.8.4. Israel Market Analysis
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Drug Class
        • 19.8.4.2.2. By Indication
        • 19.8.4.2.3. By Pet Type
        • 19.8.4.2.4. By Route of Administration
        • 19.8.4.2.5. By Distribution Channel
    • 19.8.5. South Africa Market Analysis
      • 19.8.5.1. Introduction
      • 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.5.2.1. By Drug Class
        • 19.8.5.2.2. By Indication
        • 19.8.5.2.3. By Pet Type
        • 19.8.5.2.4. By Route of Administration
        • 19.8.5.2.5. By Distribution Channel
    • 19.8.6. Northern Africa Market Analysis
      • 19.8.6.1. Introduction
      • 19.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.6.2.1. By Drug Class
        • 19.8.6.2.2. By Indication
        • 19.8.6.2.3. By Pet Type
        • 19.8.6.2.4. By Route of Administration
        • 19.8.6.2.5. By Distribution Channel

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players (%)
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional Footprint of Players
    • 20.3.2. Product Footprint of Players
    • 20.3.3. Channel Footprint of Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Key Development Analysis
  • 21.3. Branding and Promotional Strategies, By Key Players
  • 21.4. Competition Deep Dive
    • 21.4.1. Zoetis Animal Healthcare
      • 21.4.1.1. Overview
      • 21.4.1.2. Product Portfolio
      • 21.4.1.3. Key Financials
      • 21.4.1.4. Sales Footprint
      • 21.4.1.5. SWOT Analysis
      • 21.4.1.6. Strategy Overview
        • 21.4.1.6.1. Marketing Strategies
        • 21.4.1.6.2. Channel Strategies
        • 21.4.1.6.3. Product Strategies
    • 21.4.2. Merck and Co.Inc. (US)
      • 21.4.2.1. Overview
      • 21.4.2.2. Product Portfolio
      • 21.4.2.3. Key Financials
      • 21.4.2.4. Sales Footprint
      • 21.4.2.5. SWOT Analysis
      • 21.4.2.6. Strategy Overview
        • 21.4.2.6.1. Marketing Strategies
        • 21.4.2.6.2. Channel Strategies
        • 21.4.2.6.3. Product Strategies
    • 21.4.3. Boehringer Ingelheim GmbH
      • 21.4.3.1. Overview
      • 21.4.3.2. Product Portfolio
      • 21.4.3.3. Key Financials
      • 21.4.3.4. Sales Footprint
      • 21.4.3.5. SWOT Analysis
      • 21.4.3.6. Strategy Overview
        • 21.4.3.6.1. Marketing Strategies
        • 21.4.3.6.2. Channel Strategies
        • 21.4.3.6.3. Product Strategies
    • 21.4.4. Elanco Animal Health Incorporated
      • 21.4.4.1. Overview
      • 21.4.4.2. Product Portfolio
      • 21.4.4.3. Key Financials
      • 21.4.4.4. Sales Footprint
      • 21.4.4.5. SWOT Analysis
      • 21.4.4.6. Strategy Overview
        • 21.4.4.6.1. Marketing Strategies
        • 21.4.4.6.2. Channel Strategies
        • 21.4.4.6.3. Product Strategies
    • 21.4.5. Bayer AG
      • 21.4.5.1. Overview
      • 21.4.5.2. Product Portfolio
      • 21.4.5.3. Key Financials
      • 21.4.5.4. Sales Footprint
      • 21.4.5.5. SWOT Analysis
      • 21.4.5.6. Strategy Overview
        • 21.4.5.6.1. Marketing Strategies
        • 21.4.5.6.2. Channel Strategies
        • 21.4.5.6.3. Product Strategies
    • 21.4.6. Vetoquinol S.A.
      • 21.4.6.1. Overview
      • 21.4.6.2. Product Portfolio
      • 21.4.6.3. Key Financials
      • 21.4.6.4. Sales Footprint
      • 21.4.6.5. SWOT Analysis
      • 21.4.6.6. Strategy Overview
        • 21.4.6.6.1. Marketing Strategies
        • 21.4.6.6.2. Channel Strategies
        • 21.4.6.6.3. Product Strategies
    • 21.4.7. Dechra Pharmaceuticals PLC
      • 21.4.7.1. Overview
      • 21.4.7.2. Product Portfolio
      • 21.4.7.3. Key Financials
      • 21.4.7.4. Sales Footprint
      • 21.4.7.5. SWOT Analysis
      • 21.4.7.6. Strategy Overview
        • 21.4.7.6.1. Marketing Strategies
        • 21.4.7.6.2. Channel Strategies
        • 21.4.7.6.3. Product Strategies
    • 21.4.8. Virbac SA
      • 21.4.8.1. Overview
      • 21.4.8.2. Product Portfolio
      • 21.4.8.3. Key Financials
      • 21.4.8.4. Sales Footprint
      • 21.4.8.5. SWOT Analysis
      • 21.4.8.6. Strategy Overview
        • 21.4.8.6.1. Marketing Strategies
        • 21.4.8.6.2. Channel Strategies
        • 21.4.8.6.3. Product Strategies
    • 21.4.9. IDEXX Laboratories, Inc.
      • 21.4.9.1. Overview
      • 21.4.9.2. Product Portfolio
      • 21.4.9.3. Key Financials
      • 21.4.9.4. Sales Footprint
      • 21.4.9.5. SWOT Analysis
      • 21.4.9.6. Strategy Overview
        • 21.4.9.6.1. Marketing Strategies
        • 21.4.9.6.2. Channel Strategies
        • 21.4.9.6.3. Product Strategies
    • 21.4.10. Ceva Sante Animale
      • 21.4.10.1. Overview
      • 21.4.10.2. Product Portfolio
      • 21.4.10.3. Key Financials
      • 21.4.10.4. Sales Footprint
      • 21.4.10.5. SWOT Analysis
      • 21.4.10.6. Strategy Overview
        • 21.4.10.6.1. Marketing Strategies
        • 21.4.10.6.2. Channel Strategies
        • 21.4.10.6.3. Product Strategies
    • 21.4.11. Kindred Biosciences, Inc.
      • 21.4.11.1. Overview
      • 21.4.11.2. Product Portfolio
      • 21.4.11.3. Key Financials
      • 21.4.11.4. Sales Footprint
      • 21.4.11.5. SWOT Analysis
      • 21.4.11.6. Strategy Overview
        • 21.4.11.6.1. Marketing Strategies
        • 21.4.11.6.2. Channel Strategies
        • 21.4.11.6.3. Product Strategies
    • 21.4.12. Phirbo Animal Health
      • 21.4.12.1. Overview
      • 21.4.12.2. Product Portfolio
      • 21.4.12.3. Key Financials
      • 21.4.12.4. Sales Footprint
      • 21.4.12.5. SWOT Analysis
      • 21.4.12.6. Strategy Overview
        • 21.4.12.6.1. Marketing Strategies
        • 21.4.12.6.2. Channel Strategies
        • 21.4.12.6.3. Product Strategies
    • 21.4.13. Norbrook Laboratories Limited
      • 21.4.13.1. Overview
      • 21.4.13.2. Product Portfolio
      • 21.4.13.3. Key Financials
      • 21.4.13.4. Sales Footprint
      • 21.4.13.5. SWOT Analysis
      • 21.4.13.6. Strategy Overview
        • 21.4.13.6.1. Marketing Strategies
        • 21.4.13.6.2. Channel Strategies
        • 21.4.13.6.3. Product Strategies
    • 21.4.14. Vetiquinol SA
      • 21.4.14.1. Overview
      • 21.4.14.2. Product Portfolio
      • 21.4.14.3. Key Financials
      • 21.4.14.4. Sales Footprint
      • 21.4.14.5. SWOT Analysis
      • 21.4.14.6. Strategy Overview
        • 21.4.14.6.1. Marketing Strategies
        • 21.4.14.6.2. Channel Strategies
        • 21.4.14.6.3. Product Strategies
    • 21.4.15. Neogen Corporation
      • 21.4.15.1. Overview
      • 21.4.15.2. Product Portfolio
      • 21.4.15.3. Key Financials
      • 21.4.15.4. Sales Footprint
      • 21.4.15.5. SWOT Analysis
      • 21.4.15.6. Strategy Overview
        • 21.4.15.6.1. Marketing Strategies
        • 21.4.15.6.2. Channel Strategies
        • 21.4.15.6.3. Product Strategies
    • 21.4.16. PetIQ, Inc.
      • 21.4.16.1. Overview
      • 21.4.16.2. Product Portfolio
      • 21.4.16.3. Key Financials
      • 21.4.16.4. Sales Footprint
      • 21.4.16.5. SWOT Analysis
      • 21.4.16.6. Strategy Overview
        • 21.4.16.6.1. Marketing Strategies
        • 21.4.16.6.2. Channel Strategies
        • 21.4.16.6.3. Product Strategies
    • 21.4.17. Huvepharma AD
      • 21.4.17.1. Overview
      • 21.4.17.2. Product Portfolio
      • 21.4.17.3. Key Financials
      • 21.4.17.4. Sales Footprint
      • 21.4.17.5. SWOT Analysis
      • 21.4.17.6. Strategy Overview
        • 21.4.17.6.1. Marketing Strategies
        • 21.4.17.6.2. Channel Strategies
        • 21.4.17.6.3. Product Strategies
    • 21.4.18. Chanelle Pharma Group Limited
      • 21.4.18.1. Overview
      • 21.4.18.2. Product Portfolio
      • 21.4.18.3. Key Financials
      • 21.4.18.4. Sales Footprint
      • 21.4.18.5. SWOT Analysis
      • 21.4.18.6. Strategy Overview
        • 21.4.18.6.1. Marketing Strategies
        • 21.4.18.6.2. Channel Strategies
        • 21.4.18.6.3. Product Strategies
    • 21.4.19. Kepro
      • 21.4.19.1. Overview
      • 21.4.19.2. Product Portfolio
      • 21.4.19.3. Key Financials
      • 21.4.19.4. Sales Footprint
      • 21.4.19.5. SWOT Analysis
      • 21.4.19.6. Strategy Overview
        • 21.4.19.6.1. Marketing Strategies
        • 21.4.19.6.2. Channel Strategies
        • 21.4.19.6.3. Product Strategies
    • 21.4.20. Biogenesis Bago
      • 21.4.20.1. Overview
      • 21.4.20.2. Product Portfolio
      • 21.4.20.3. Key Financials
      • 21.4.20.4. Sales Footprint
      • 21.4.20.5. SWOT Analysis
      • 21.4.20.6. Strategy Overview
        • 21.4.20.6.1. Marketing Strategies
        • 21.4.20.6.2. Channel Strategies
        • 21.4.20.6.3. Product Strategies

22. Assumptions and Acronyms Used

23. Research Methodology